For the latest COVID-19 information for Massey, visit masseycancercenter.org/covid-19

News Center

Latest News

Center News & Funding

Researcher Steven Grant assumes prestigious roles at the National Cancer Institute

Nov 16, 2011

GrantStevennew-crop

World renown for his development of novel drug combinations to treat blood cancers, VCU Massey Cancer Center researcher Steven Grant, M.D., has been asked to serve the National Cancer Institute (NCI) as a member of their Investigational Drug Steering Committee (IDSC) and as IDSC Lymphoma Expert and Liaison to the Lymphoma Steering Committee (LYSC).

Shirley Carter Olsson and Sture Gordon Olsson Chair in Oncology Research, associate director for translational research and program co-leader of Developmental Therapeutics at VCU Massey, Grant will facilitate many important activities in his role on the IDSC, including conducting strategic discussions about early phase drug development trials, providing initial and ongoing input on clinical development plans for investigational drugs, assessing letters of intent submitted by researchers who wish to carry out clinical trials using Cancer Therapy Evaluation Program (CTEP) investigational drugs and addressing scientific or clinical questions about early stage clinical trials. As IDSC’s Lymphoma Expert and Liaison to the LYSC, Grant will help facilitate communication and collaboration between the IDSC and LYSC.

The IDSC was created in November 2005 and is composed of the Steering Committee, 10 NCI task forces and three NCI working groups. It provides the NCI with scientific and clinical input on the design and prioritization of Phase I and II clinical trials with agents for which CTEP holds an investigational new drug application. The goal of the IDSC is to create more successful Phase III clinical trials by ensuring early phase clinical trials are well designed.

The LYSC was created in 2009 to promote efficient, cost-effective and science-driven clinical research on lymphoma and related diseases by evaluating the design and prioritization of Phase III and large Phase II clinical trials. It is comprised of representatives from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN), AIDS Malignancy Consortium (AMC), Specialized Programs of Research Excellence (SPORE) investigators, community oncologists, biostatisticians, patient advocates and NCI staff.

Written by: John Wallace

Related News

Center News & Funding

Massey physicians named Richmond’s “Top Docs”

Center News & Funding, Community Engagement & Health Equity

Support your doctor on National Doctors' Day

Center News & Funding, Clinical, Prevention & Control

Massey specialists awarded $5 million to enhance lung cancer screening and treatment for veterans

Get access to new, innovative care

Get access to new, innovative care

Treatments in clinical trials may be more effective or have fewer side effects than the treatments that are currently available. With more than 200 studies for multiple types of cancers and cancer prevention, Massey supports a wide array of clinical trials.

Search clinical trials
Find a provider

Find a provider

Massey supports hundreds of top cancer specialists serving the needs of our patients. Massey’s medical team provides a wealth of expertise in cancer diagnosis, treatment, prevention and symptom management.

Find a provider